文献速递脑血管病

既往抗血小板治疗对直接血管内治疗的大血管闭塞性急性缺血性卒中结局的影响

Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.
PubMed 文献 · Neurology · 2026-02-11

本研究基于欧洲多中心EVA-TRISP登记库(2015-2023),回顾性分析前循环大血管闭塞、未接受静脉溶栓或抗凝的直接血管内治疗患者,比较既往抗血小板治疗与否的90天功能结局。倾向评分匹配后显示,既往任何抗血小板治疗与90天mRS评分降低(OR 1.30)及独立生活率提高(OR 1.62)相关,且不增加症状性颅内出血或死亡风险。

要点

  • 直接EVT前既往抗血小板治疗与90天功能结局改善独立相关。
  • 既往抗血小板治疗不增加症状性颅内出血和死亡风险。
  • 该关联不受闭塞部位或发病至穿刺时间是否超过6小时影响。

核心结论

  • 在前循环大血管闭塞接受直接EVT且未抗凝的患者中,既往任何抗血小板治疗与更好的90天功能结局和更高独立率独立相关,不增加sICH风险。

研究设计与样本

  • 回顾性分析EVA-TRISP登记库中2015-2023年9个欧洲国家和以色列20个高容量卒中中心的连续患者。
  • 纳入前循环LVO、未接受IVT或抗凝的成人,按既往APT方案分层,采用倾向评分匹配和多水平模型校正混杂。
  • 12,950例中2,611例符合标准,匹配1,308例:无既往APT 480例,任何既往APT 828例(单药764例,双联64例)。

主要发现

  • 匹配队列平均年龄75.8±11.4岁,女性49.4%,平均NIHSS评分13.1±7.2分,成功再灌注率74.7%,mRS中位数3(IQR 2-4),90天独立率38.8%。
  • 与无既往APT相比,任何既往APT与90天mRS评分向更低方向偏移相关(OR 1.30,95%CI 1.04-1.61,p=0.018)。
  • 任何既往APT与90天独立相关(OR 1.62,95%CI 1.22-2.16,p=0.001)。
  • 任何既往APT与成功再灌注(OR 0.96,95%CI 0.69-1.35,p=0.821)、sICH(OR 1.06,95%CI 0.47-2.39,p=0.880)或死亡(OR 0.89,95%CI 0.66-1.21,p=0.821)无显著关联。
  • 既往APT与闭塞位置(近端/远端,p=0.213)或发病至穿刺时间(早于/晚于6小时,p=0.743)无显著交互作用。

临床怎么用

  • 对于前循环LVO且未接受IVT或抗凝、拟行直接EVT的患者,既往抗血小板治疗不应被视为增加出血风险或影响疗效的不利因素。
  • 临床决策时可参考既往抗血小板治疗状态评估功能预后,但需结合个体情况综合判断。

局限性

  • 回顾性研究设计,存在选择偏倚和未测量混杂的可能。
  • 仅纳入未接受IVT或抗凝的患者,结论不能外推至接受IVT或抗凝的患者。
  • 双联抗血小板治疗亚组样本量较小(64例),未单独分析其效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. METHODS: We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. RESULTS: Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61, p = 0.018). Independence at 90 days was associated with any previous APT (OR 1.62, CI 1.22-2.16, p = 0.001). Any previous APT was not associated with successful reperfusion (OR 0.96, CI 0.69-1.35, p = 0.821), sICH (OR 1.06, CI 0.47-2.39, p = 0.880), or mortality (OR 0.89, CI 0.66-1.21, p = 0.821). There was no significant interaction between any previous APT and proximal/distal occlusion location (p = 0.213) or time-to-groin earlier/later than 6 hours (p = 0.743). DISCUSSION: In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Benci Z, Bianco G, Disanto G, et al. Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy. Neurology. 2026. PMID: 41671526. doi:10.1212/WNL.0000000000214672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。